Related Experiment Video
Updated: May 14, 2026
09:32
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Imatinib-induced Stevens-Johnsons syndrome.
Praveen Jha1, D Himanshu, Nirdesh Jain
1Department of Internal Medicine, KGMU., Gwalior, Madhya Pradesh, India.
BMJ Case Reports
|January 26, 2013
Summary
Imatinib mesylate, a CML treatment, can cause rare but severe skin reactions. This case highlights Steven-Johnsons syndrome as a potential adverse effect requiring drug withdrawal.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Imatinib mesylate is a standard first-line therapy for chronic myeloid leukaemia (CML).
- Common side effects include fluid retention, diarrhea, and skin rashes like maculo-papular eruptions.
- Severe cutaneous adverse reactions are infrequent but can be life-threatening.
Observation:
- A patient with newly diagnosed CML developed Steven-Johnsons syndrome during imatinib therapy.
- This severe skin reaction is a rare adverse event associated with imatinib.
Findings:
- The patient's Steven-Johnsons syndrome was directly linked to imatinib treatment.
- Successful management involved discontinuing the imatinib medication.
Implications:
- This case underscores the importance of monitoring for rare, severe dermatological side effects in CML patients treated with imatinib.
- Prompt recognition and drug withdrawal are crucial for managing life-threatening cutaneous reactions.
- Highlights the need for vigilance regarding imatinib's potential for severe skin reactions beyond common eruptions.
More Related Videos
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...